Press conference held to announce the commencement of an international trial for inherited Alzheimer's disease

A research group led by Professor Takeshi Ikeuchi, Assistant Professor Kensaku Kasuga (both from BRI Dept of Molecular Genetics) and Dr Yoshiki Niimi (Specially Appointed Associate Professor at the University of Tokyo) has launched the DIAN NexGen* global clinical trial for inherited Alzheimer's disease. This trial is named "A phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease." The trial will test the effects of a combination of anti-amyloid-β and anti-tau antibody drugs on biomarkers and cognitive function in individuals with a genetic mutation that causes inherited Alzheimer's disease.

A press conference was held on this matter on Thursday 14 March by the three aforementioned scientists.

The results of this trial are expected to accelerate the development of treatments for sporadic Alzheimer's disease, which affects a large number of patients, in addition to inherited Alzheimer's disease.

*The Dominantly Inherited Alzheimer's Network (DIAN) is an international research consortium dedicated to dominantly inherited Alzheimer's disease (DIAD). DIAD, a form of Alzheimer's disease (AD), results from a genitive mutation, accounting for less than 1% of all AD cases. It typically occurs between the ages of thirties and fifties, leading to memory loss and dementia. The primary objective of DIAN research is to discover methods for treating or preventing the disease. DIAN NexGen represents a collaborative DIAD treatment
記者へ説明を行う池内健教授 アミロイド蓄積の時間的推移を示したスライド 新大病院における治験の責任者を務める春日健作助教